| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Investors with a lot of money to spend have taken a bearish stance on Teva Pharmaceutical Indus (NYSE:TEVA).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TEVA, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 9 options trades for Teva Pharmaceutical Indus.
This isn't normal.
The overall sentiment of these big-money traders is split between 11% bullish and 88%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $30,712, and 8, calls, for a total amount of $290,170.
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $15.0 to $22.0 for Teva Pharmaceutical Indus over the last 3 months.
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Teva Pharmaceutical Indus's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Teva Pharmaceutical Indus's significant trades, within a strike price range of $15.0 to $22.0, over the past month.
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TEVA | CALL | SWEEP | BEARISH | 09/20/24 | $1.47 | $1.43 | $1.43 | $17.00 | $71.5K | 19.2K | 781 |
| TEVA | CALL | TRADE | BEARISH | 12/20/24 | $2.14 | $2.1 | $2.1 | $17.00 | $42.0K | 12.4K | 200 |
| TEVA | CALL | SWEEP | BEARISH | 01/16/26 | $1.99 | $1.92 | $1.92 | $22.00 | $35.3K | 107 | 184 |
| TEVA | PUT | TRADE | BEARISH | 01/17/25 | $0.88 | $0.87 | $0.88 | $15.00 | $30.7K | 2.8K | 350 |
| TEVA | CALL | TRADE | BEARISH | 09/20/24 | $2.03 | $2.0 | $2.01 | $16.00 | $30.5K | 35.6K | 413 |
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
In light of the recent options history for Teva Pharmaceutical Indus, it's now appropriate to focus on the company itself. We aim to explore its current performance.
2 market experts have recently issued ratings for this stock, with a consensus target price of $20.0.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Teva Pharmaceutical Indus with Benzinga Pro for real-time alerts.
Posted In: TEVA
